On the basis of my personal clinical and research experience and validated by the current literature, my approach to the management of pediatric (age o18 years) and young patients (age o40 years) with classic myeloproliferative neoplasms is presented by focusing on diagnosis, patient communication, risk stratification and therapy. The WHO-2008 diagnostic criteria are recommended, even though in children suspected with essential thrombocythemia (ET), a specific set of diagnostic features may be required. Patient communication includes information on natural history, genetic abnormalities and counseling in all women of child-bearing age. The main challenge in children and young adults with ET and polycythemia vera (PV) is to avoid recurrence of major thrombosis by selecting those patients who ultimately can benefit from cytotoxic and antithrombotic therapy without increasing the incidence of drug-induced side effects. In asymptomatic low-risk patients no therapy is prescribed while in high-risk low-dose aspirin, hydroxyurea and interferon-alpha are my first line drugs. My first decision when considering treatment of a young patient with primary myelofibrosis (PMF) or post-PV or post ET-myelofibrosis, is whether he/she qualifies for bone marrow allotransplantation. In the remaining young PMF patients palliative therapy or experimental drugs are considered.
INTRODUCTION
Polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) are currently classified among the bcr/abl-negative, 'classic' myeloproliferative neoplasms (MPNs) and represent a stem cell-derived clonal myeloproliferation. Hematopoietic progenitors derived from patients with MPNs are hypersensitive to the stimulation of physiological growth factors such as thrombopoietin or erythropoietin (EPO). 1 Since 2005, the pathophysiology of these diseases has advanced considerably with the discovery of an acquired mutation of JAK2 V617F in a vast majority of PV patients and in almost half of those with ET and PMF. 2 The mutation, located within the negative regulatory pseudokinase, or Janus homology 2 domain, causes cytokine-independent activation of several biochemical pathways implicated in EPO receptor signaling. Subsequently, mutations in MPL were reported in B4% of patients with ET or PMF. The significance of JAK2 and MPL mutations for the evolution of the MPNs and their relative roles in determining disease phenotype as well as progression to myelofibrosis and leukemic transformation are unclear at present.
In this context, it should be underscored that most of the information in terms of diagnosis, prognosis and therapy focuses on the 'average' MPN patients of whom median age ranges between 60 and 65 years. On the other hand, less consistent data are available in the groups of MPN patients who are presenting below this median age such as pediatric and young adults (20% of MPN patients). This issue is now becoming more and more important, because with the advent of automatized blood cell counters in the past years, new cases of MPNs are diagnosed in young patients with increasing frequency.
This article is based on my personal clinical and research experience and is validated by the currently published literature.
I will discuss my approach to the management of pediatric (ageo18 years) and young patients (ageo40 years) with classic MPNs focusing on the salient points as diagnosis, patient communication, risk stratification and therapy.
HOW TO DIAGNOSE MPN IN CHILDREN AND YOUNG ADULTS
In 2007/8, the WHO investigators proposed criteria and algorithms for MPN diagnosis. 3, 4 These criteria combine genetic, clinical and pathological characteristics and emphasize the neoplastic nature of the previously termed myeloproliferative diseases and renamed them MPNs.
Polycythemia vera For PV diagnosis, the WHO requires the demonstration of increased hemoglobin/hematocrit levels with the presence of JAK2 mutation (major criteria) and one minor criterion as well. In the absence of the second major criterion (JAK2 or related mutations), at least two of three minor supportive criteria should be demonstrable that are low EPO blood level, characteristic morphological features of bone marrow biopsies and spontaneous erythroid colonies. Contrary to previous recommendations, red cell mass measurement is no longer required.
In my practice, in children with elevated hemoglobin and hematocrit (HCT) levels the diagnostic algorithm includes a number of steps: the first is to exclude congenital heart diseases, then it is necessary to check the EPO levels. If EPO level turns out to be low, primary erythrocytosis might be suspected and the work-up is focused on the diagnosis of PV (JAK2 mutation) or familial and congenital polycythemia (EPO receptor gene mutations), particularly in cases of JAK2 or JAK2 exon-12 negativity. If EPO levels are normal or elevated, extrinsic influences have to be considered such as secondary causes of increased EPO production and other conditions including hemoglobin variants, von Hippel --Lindau gene mutations and 2,3 phosphoglycerate deficiency.
Essential thrombocythemia Diagnosis of ET requires the meeting of four criteria: first, platelet count of at least 450 Â 109/l; second, bone marrow biopsy specimens showing proliferation mainly of the megakaryocytic lineage with increased numbers of enlarged, mature megakaryocytes and no significant increase or left-shift of neutrophil granulopoiesis or erythropoiesis; third, not meeting the WHO criteria for PV, PMF, chronic myeloid leukemia (CML), myelodysplastic syndromes (MDS) or other myeloid neoplasms; fourth, demonstration of JAK2 or other clonal marker, or, in the absence, no evidence for reactive thrombocytosis. My approach in children with thrombocytosis who are negative for the JAK2 mutation (40 --50%), is the exclusion of any infectious, rheumatological, autoimmune or neoplastic conditions. Of note is that the WHO diagnostic recommendations in children suspected with ET are thought to be not adequate and a specific set of diagnostic criteria is required. 5, 6 Contrary to adults, most of children with ET present polyclonal, rather than monoclonal hematopoiesis, the capacity to form spontaneous colonies is present less often and the presence of JAK2 mutation is significantly less frequent than in the general MPN population. Therefore, the WHO criteria cannot be used for the diagnostic screening of these young patients. Diagnosis of ET in children may require exclusion of hereditary manifestations transmitted as hereditary character, involving genetic defects of thrombopoietin receptor, thrombopoietin and MPL mutations expressed in both somatic and germ line cells. 7 
Primary myelofibrosis
The proposed 2008 WHO criteria for PMF are applicable in children and young adults. Bone marrow histology is essential to exclude secondary causes of myelofibrosis (neoplastic and non-neoplastic) and the prefibrotic phase of PMF that presents a different natural history in comparison with true ET. 8 It should be considered that both the familial and idiopathic forms of PMF may be associated with congenital anomalies and chromosomal abnormalities. 9 Del(20q) or del(13q) as well as normal karyotype are associated with a favorable prognosis, whereas most other cytogenetic aberrations render a negative prognostic impact. 10, 11 Fewer than 100 cases of pediatric myelofibrosis have been reported worldwide and approximately half of published cases occurred in children younger than 3 years. These latter patients are more likely to have Down's syndrome, rickets or a familial (possibly autosomal recessive) form of myelofibrosis. Among older children, systemic lupus erythematosus, tuberculosis and acute myeloid leukemia (AML), which has usually a fulminant course (survival o1 year), are the most common associations. 12, 13 HOW TO COMMUNICATE THE DISEASE As soon as the diagnosis is established, I explain in details the natural history of the disease. The onset of the MPNs is often a very slowly advancing process and both in the WHO-defined PV and ET, disease-specific survival (loss in life expectancy) is not substantially different from that of a control population, especially in younger adults.
14 PMF is a more serious disease with expected median observed survival of about 6 years, 15 whereas in prefibrotic myelofibrosis median survival is about 10 years. 14 Information on the genetic abnormalities most commonly encountered in MPNs has to be explicitly discussed. The concern regarding the possibility that MPNs can be heritable should be addressed in this context by emphasizing that the vast majority of MPN cases are sporadic and that the genetic mutation of JAK2 is not a predisposing factor. However, familial clustering of PV, ET and PMF has been well described and patients should know that occasionally other members of the family may present these disorders. 16, 17 In accordance with the European Leukemia Net (ELN) investigators, 18 in the absence of hematological or clinical abnormalities, I do not routinely genotype for JAK2 mutations or JAK2 46/1 (GGCC) haplotype the relatives of individuals with MPNs. 19 Patients should be notified that follow-up of PV, ET and to lesser extent early/prefibrotic PMF 20 is marked by thrombohemorrhagic complications, constitutional symptoms, such as pruritus, night sweats, fatigue and a propensity to transform into overt myelofibrosis (10 --25%), and acute leukemia (o5%), however, at different incidence concerning the disease entities. It has to be emphasized in detail that drugs are chosen to reduce thrombosis and bleeding events and should be balanced in consideration of the risks associated with their long-term use. Therefore, in children and young adults, cytotoxic agents will be prescribed to prevent severe vascular recurrences and it should be clarified that with exception of allotransplantation, current drug therapy is not able to eradicate the malignant clone. In my opinion, the relevance of coexisting thrombophilic factors to justify cytoreductive therapy in low-risk asymptomatic patients is not yet well established. Thus, in the absence of familial recurrent vascular events, I consider it not to be very helpful to test for hereditary thrombophilic or acquired factors such as the congenital deficiencies of natural anticoagulants (antithrombin, protein C and protein S) and genetic mutations (factor V Leiden and prothrombin G20210A).
Regarding PMF, patients should be informed about prognosis that usually is even in the prefibrotic stages more severe compared with PV and ET.
14 The International Prognostic Scoring System (IPSS) for classical-advanced PMF uses five independent predictors of inferior survival (age 465 years, hemoglobin o10 g/100 ml, leukocyte count 425 Â 109/l, circulating blasts 41% and presence of constitutional symptoms) to stratify patients into low, intermediate-1, intermediate-2 and high-risk categories based on the presence of 0, 1, 2 or 43 risk factors, respectively; the corresponding median observed survivals are estimated at 135, 95, 48 and 27 months. 15 On the other hand, it has to be tested whether this International Prognostic Scoring System may be also applicable on patients with early PMF that infrequently present with constitutional symptoms.
All women of child-bearing age should adequately be counselled concerning the potential dangers and complications of the disease during pregnancy and potential consequences for the child. 21, 22 Concerning contraception, there is currently insufficient evidence either to support or refute an association between estrogen-based hormonal treatment and thrombosis in MPNs. 23 My suggestion is to avoid the use of estrogen-based contraceptives in MPNs and to use alternative methods. In the event that reproductive therapy is indicated, patient should be informed that ovarian hyperstimulation may be associated with increased risk of thrombosis and that antithrombotic prophylaxis may be indicated.
HOW TO MANAGE CHILDREN
Polycythemia vera PV in children and adolescents is very rare. The incidence before the age of 25 years, accounts 1/10 000.000. On the contrary in adults, with a median age at presentation of 60 years, the incidence is around 10 --20 cases per 1 000 000. Owing to the rarity of MPN in children o18 years, very few studies with limited number of patients are available. 5, 24 An extensive review of the literature describing the clinical course and treatment modalities of 35 PV cases in children was recently reported. 25 The youngest was 7 months and the oldest 17.5 years old (median age 11 years). Budd-Chiari syndrome was the prevalent complication and it is recommended to take this event into account even though diagnosis may not be clinically obvious. In fact, concurrent hypersplenism, occult gastrointestinal bleeding or hemodilution can mask blood count abnormalities. Of significant diagnostic help is the determination of JAK2 mutation, which is found in about 45% of adult patients with Budd-Chiari syndrome and in 34% with portal vein thrombosis. However, it should not be overlooked that negativity of this mutational status does not exclude MPDs. Other described complications in children include stroke, cerebral vein thrombosis and severe hemorrhage. 26 Essential thrombocythemia ET is also rare in children o18 years and no sufficient data to recommend treatment are available, especially as in the current literature the WHO criteria for ET were not stringently applied. 8, 27 Moreover, no evidence for a risk stratification particularly useful to guide therapeutic decisions is available and there are no indications on how to monitor cytoreductive therapy. In adults, ELN recently reported criteria for monitoring therapy. 28 In particular, It has been emphasized that all studies in PV and ET failed to show a clear association between platelet count and thrombotic events. Rather, functional and structural platelet abnormalities are of more relevance. Paradoxically, very high platelet counts can induce a bleeding tendency, mainly due to an acquired Von Willebrand's disease. 29 I fully agree with ELN recommendations that cytoreductive drugs in children with PV and ET should be prescribed as a last possibility and I suggest that, in the rare cases that need treatment, the selection of a cytotoxic or cytoreductive agent should be done after discussion with the child and parents. Hydroxyurea (HU) and interferon-alpha (IFN-a) are first line therapy at any age including children and young adults. The long-term leukemogenicity of HU may be a special concern, although none of the pediatric patients treated with this agent have yet undergone malignant transformation. 27, 30 Adverse effects of IFN-a such as flu-like syndrome, neuropsychiatric symptoms and autoimmune phenomena can be particularly dangerous for children. Anagrelide is not licensed as first-line therapy for ET in Europe and the ELN group recommends this drug as second line therapy. 18 The use of aspirin (ASA) in children less than 12 years of age should be prescribed with caution because of the risk of Reye's syndrome. Overall, according to ELN experts, there are insufficient data to recommend a specific agent in children, and the choice should be individually tailored.
Primary myelofibrosis Natural history of PMF in children seems different from the adult variant. Variable outcomes with either fulminant course rapidly evolving to acute leukemia or relative indolent courses have been described. A thorough search for an underlying disease should be made in order to exclude secondary myelofibrosis. 31 --33 The only effective therapy in acute leukemia phase lies in allogeneic bone marrow transplantation. Indolent disease may respond to corticosteroid.
--33

WHAT TO DO IN ASYMPTOMATIC YOUNG ADULT PATIENTS WITH PV AND ET
The main challenge in young adults with classic MPNs is to select those patients who ultimately can benefit from a therapy without increasing the incidence of life threatening side effects of the long use of cytotoxic drugs ( Table 1) .
Cornerstone of treatment for PV is represented by phlebotomy. The immediate goal of this practice is to reduce hyperviscosity by decreasing the venous HCT level to less than 45%. This strategy is based on PV Study Group investigations that reported the best median observed survival of 12.6 years for this type of treatment. 34 However, some experts have cast doubts on these findings, noting that up to 50% of patients treated with phlebotomy alone had to switch to other therapies by the fifth year. 35 Moreover, in the ECLAP (European Collaborative Low-dose Aspirin in Polycythemia) Study, multivariate analysis considering all the confounders failed to show any correlation between HCT values in the range from 40 to 50% and incidences of thrombosis. 36 This uncertainty prompted Italian investigators to activate a prospective, multicenter, randomized clinical study (CYTO-PV) addressing the issue of the optimal target of cytoreduction in PV (EudraCT 2007-006694-91). While waiting for the results of this trial, my practice is to follow ELN recommendations and to perform phlebotomy withdrawing 250 to 500 ml of blood daily or every other day until a HCT value between 40 and 45% is obtained. Once normalization of the HCT has been obtained, blood counts at regular intervals (every 4 to 8 weeks) will establish the frequency of future phlebotomies. Supplemental iron therapy should not be given as iron depletion may impose a constrain to erythropoiesis.
The use of low-dose ASA is considered the second mainstay for patients with PV. This statement is based on the ECLAP double blind placebo controlled randomised clinical trial, in which a benefit of 100 mg ASA in reducing major thrombosis in PV was demonstrated. 37 In this trial, after a follow-up of about 3 years, there was a statistically significant 59% reduction of major thrombosis (both arterial and venous) without a significant increase in hemorrhagic complications in the ASA group.
Contrary to PV, there are many uncertainties to indicate ASA as primary prophylaxis in low-risk ET. A recent publication questions the benefit of low-dose ASA in this group of patients. 38 These investigators concluded that antiplatelet therapy may be associated with a reduction of the incidence of venous thrombosis in JAK2-positive patients and that ASA may decrease the frequency of arterial thrombotic events in patients with associated cardiovascular risk factors. In the remaining low-risk patients (JAK2 negative and no risk factors), the net benefit of ASA in terms of reduction of thrombosis associated with no increase in bleeding was not favorable. Interestingly, the bleeding risk of ASA has been reported significantly higher in thrombocythemic patients presenting with a bone marrow morphology of early PMF (12% of bleeders) as opposed to those with bone marrow pictures typical of true ET (6% of bleeders). In this series of more than 1000 strictly the WHO-defined patients, the crucial role of leukocytosis, in addition to thrombocytosis, has been demonstrated by correcting with meaningful confounders. 39 In my daily routine I prescribe low-dose ASA (75 --100 mg) in low-risk patients with erythromelalgia and limit the long-term use of this drug in young ET asymptomatic cases in which serious hemorrhagic problems can occur at any age including children. 26 Thus, I carefully assess the individual thrombotic and hemorrhagic risk by looking in particular, at previous conditions with a high bleeding risk (that is, gastric ulcers or esophageal varices High-risk patients as above, plus myelosuppressive therapy: hydroxyurea as first choice; PEG-interferon in special situations (that is, pregnancy); in ET patients intolerant or refractory to hydroxyurea PEG-interferon or Anagrelide.
Abbreviations: ET, essential thrombocythemia; PV, polycythemia vera.
Myeloproliferative neoplasm vs children and young adults T Barbui secondary to splanchnic vein thrombosis and portal hypertension), and in patients with extreme thrombocytosis I require that ristocetin cofactor activity should be 430%. In asymptomatic ET and PV young patients a safer alternative is an aggressive management of modifiable thrombotic risk factors, such as diabetes, hypertension, obesity and metabolic syndrome, and in particular, patients should be requested to stop smoking. In line with other clinicians, in otherwise low-risk patients carrying well-controlled cardiovascular risk factors, I do not use cytotoreductive drugs. 40 More recently, JAK2 mutation and leukocytosis have been recognized as independent predictors of major thrombosis, particularly in low-risk ET patients. 41 However, these novel biomarkers might be incorporated in the risk classification, possibly allowing better definition of the low-risk group, once they have been eventually validated in prospective studies.
WHAT TO DO IN YOUNG PATIENTS WITH THROMBOSIS
Although it is generally recognized that young age identifies patients at lower thrombotic risk, the actuarial rate of major thrombosis is higher than in general population of the same age. Therefore, a proportion of PV and ET patients with age o40 years needs to receive cytoreductive drugs. Limited information is available regarding results of therapy that varies enormously. In the reported series of young adults with PV and ET, the most used drugs were ASA, phlebotomy, HU, IFN-a, and also alkylating agents as pipobroman, busulfan, melphalan. In one study the standardized mortality ratio in 70 PV patients younger than 50 years was 5.3%, indicating a life expectancy markedly lower than the control population. 42 Causes of death in this study were mainly owing to an excess of hematological transformation in AML or post-PV myelofibrosis. These latter events occurred after 9 years of follow-up and were likely due to long-term exposure of cytotoxic drugs that were pipobroman in 73% and HU in 9%. Only 18% of this young people received phlebotomy as the sole therapy. In contrast, in a cohort of 36 PV patients, median age of 37 years (range 19 --45 years), treated exclusively with phlebotomy, ASA and HU, no secondary leukemia or cancer were observed during a follow-up of 14 years and the incidence of thrombosis was comparable to other series. 43 The largest prospective evaluation of risk factors for survival, incidence of thrombosis and hematological transformation is the ECLAP observational cohort study. 44 Patients younger than 65 years in the ECLAP Study had the lowest rate of thrombosis (2.5% patients per year), while with age older than 65 years and a positive history of thrombosis, the corresponding rate ranged from 6 to 10% patients per year. Of note were a consistent association between age 465 years and risk of leukemia and between duration of disease with risk of overt myelofibrosis.
In ET patients younger than 40 years, thrombosis varies from 10 to 16% at 10 years and the development of leukemia or overt myelofibrosis is rarely reported. 45, 46 Antithrombotic drugs and the use of cytoreductive therapy to control the myeloproliferative process are the mainstay of secondary prophylaxis.
Concerning prophylaxis with antithrombotic drugs, I suggest to define whether the thrombotic event has been provoked by some triggers or has occurred without demonstrable possible causes. In patients with unprovoked vein thrombosis including splanchnic vein thrombosis and Budd-Chiari syndrome, I prescribe long-term use of oral anticoagulants. This is supported by a large series of patients showing a 68% risk reduction of recurrent thrombosis. 47 In contrast, in provoked leg vein thrombosis, warfarin prophylaxis, along with cytoreductive drugs, may last 1 year. Antiplatelet agents given as maintenance showed to lead to a 58% risk reduction of recurrence. 47 In patients with coronary syndromes or any other peripheral arterial thrombotic event, ASA alone or in combination with clopidogrel antiplatelet drugs are used according to current guideline.
In regard to cytoreductive drugs, HU is my first choice when a young patient with PV or ET has experienced a life-threatening major thrombotic event (stroke, myocardial infarction, peripheral arterial thrombosis, deep-vein thrombosis, including cerebral thrombosis and Budd-Chiari syndrome). The latter applies also to patients with poor tolerance to, or high need for phlebotomy, symptomatic or progressive splenomegaly and severe disease related symptoms, platelet counts greater than 1.5 Â 10 9 /l or progressive leukocytosis. The starting dose of HU is 15 --20 mg/kg/ day until response is obtained. To keep the response, a maintenance dose is administered without reducing white blood cell count values below 2500 Â 109/l and supplemental phlebotomy should be performed if needed in PV patients. My practice is to control the complete hemogram in every 2 weeks during the first 2 months, then every month, and, in steady state responding patients, every 3 months. It is unclear if ELN criteria for response are valuable in daily routine of these patients. In a recent paper the rate of thrombosis was reported to be significantly reduced by HU, independently on the achievement of complete or partial response. 48 Some patients may be reluctant to use HU because of fear regarding its possible leukemogenicity, but they should be informed that to date, no robust data supporting such hypothesis in either ET or PV is available. In a nationwide cohort of 11 039 MPN patients, a nested case --control study including 162 AML patients and 242 matched controls showed that the risk of AML was similar to that of controls and not significantly increased by HU given as sole therapy. 49 Remarkably, 25% of patients who developed leukemia were never exposed to cytotoxic therapy supporting the notion of a major role for intrinsic MPN-related factors in overall leukemogenesis. However, in a recent long-term analysis of a randomized clinical trial comparing HU with pipobroman in 292 PV patients (median follow-up 16.3 years), median survival was 20.3 years in the HU arm and 15.4% in pipobroman arm. Cumulative incidence of AML/MDS at 10, 15 and 20 years was 6.6%, 16.5% and 24% in the HU and 13%, 34% and 52% in the pipobroman arm, respectively, (P ¼ 0.004). 50 Importantly, HU-associated leukemia could be a relatively frequent event when given before or after alkylating agents or radiophosphorus. 51 Major side effects of HU include neutropenia, macrocytic anemia and muco-cutaneuos toxicity, most frequently presenting as oral and leg ulcers and skin lesions. In a recent survey the rate of these events was less than 5%. 52 As suggested by the ELN, an alternative option as first line therapy in high-risk PV and ET is IFN-a. 18 This drug is known to be non-leukemogenic, but it is associated with side effects leading to withdrawn in about 20% of patients. Pegylated forms of IFN-a allow weekly administration, potentially improving compliance and possibly providing more effective therapy. In PV complete responses according to ELN criteria both in PV and ET were reached in a great proportion of cases and no thrombohemorrhagic complications were registered during follow-up. Interestingly, the malignant clone tested in PV, as quantitated by the percentage of the mutated JAK2V617F, was reduced. 53, 54 However, whether this drug is more efficacious than HU in reducing the rate of thrombosis remains to be demonstrated. The evidence to indicate IFN-a as the drug of choice in any ET and PV patient younger than 60 years and in hypercellular/early PMF 55 is not yet supported by clinical trials. There is great expectation from an ongoing clinical trial that compares head to head HU (standard treatment) and IFN-a (experimental drug). My current practice is to prescribe IFN-a in very selected young patients resistant or intolerant to HU 56 and in special situations such as pregnancy. In regard to anagrelide, the UK-PT1 Study has compared the drug with HU. 57 Patients in the anagrelide arm showed an increased rate of arterial thrombosis, major bleeding and myelofibrotic transformation, but a decreased incidence of venous thrombosis compared with HU. In addition, anagrelide was more poorly tolerated than HU and presented significantly greater rates of cardiovascular, gastrointestinal, neurological and constitutional side effects. Transformation to AML was comparable between the two arms (four patients in the anagrelide versus six in the HU arm), although the small number of transformations and short follow-up prevent any valid conclusions about leukemogenicity. Anagrelide appears to provide partial protection from thrombosis, particularly in JAK2 V617F-negative ET patients, and may therefore be suitable as second line therapy for patients in whom HU is inadequate or not tolerated, according with the criteria described above.
Therapy with anagrelide, but not with HU, was also associated with progressive anemia and an increase in bone marrow fibrosis. 58 Therefore, follow-up trephine biopsies are recommended for patients receiving this agent, perhaps every 2 --3 years. However, it should be noted that the diagnosis of ET in the UK-PT1 trial was made according to the PV Study Group classification 59 and it remains questionable if the UK-PT1 study results can be applied to ET patients diagnosed according to the WHO-classification. 60 In this connection, useful information is expected from the Anahydret Trial. 61 
HOW TO MANAGE YOUNG ADULTS WITH PMF
My first decision when considering treatment of a young patient with PMF or post-PV or post ET-myelofibrosis, is whether he/she qualifies for bone marrow allotransplantation, which can be potentially curative (Table 2) . I select patients according to the International Prognostic Scoring System score and indicate the procedure in cases with intermediate 2 (median survival 48 months) or high risk (median survival 27 months) as well as those with either need for red blood cell transfusion (median survival B20 months) or unfavorable cytogenetic abnormalities (median survival B40 months). The estimated 1 year treatment-related mortality associated with conventional intensity conditioning regimens averages about 30% and overall survival 50%. 62 Therefore, I favor the risk-benefit ratio of allogeneic transplantation in high-risk young patients with PMF. Given that no other therapy has been proved to render a survival advantage, the remaining patients must be treated in palliative manner or in experimental clinical trials. In anemic patients, treatment with red blood cell transfusions is the mainstay of palliative treatment. Corticosteroids, androgens, EPO and immunomodulators might be considered and in cases of del(5q), lenalidomide is preferred.
2 Long-term periodic transfusions can be complicated by hemosiderosis and may require the use of chelating agents. However, according to ELN, 18 iron-chelating therapy is not indicated except in allotransplantation. Unfortunately, results of any treatment for patients with blast phase of MPNs (median survival 6 months) are extremely poor. In selected candidates aggressive induction chemotherapy followed by consolidation with allogeneic stem cell transplantation may be considered.
MY ADVICE TO YOUNG PATIENTS IN RELATION TO CLINICAL TRIALS WITH JAK2 INHIBITORS?
The efficacy of novel JAK2 inhibitors seems promising, 63, 64 so that I encourage PMF and PV/ET patients with symptomatic refractory splenomegaly and severe constitutional symptoms to participate in clinical trials. However, I underscore that there is no evidence that these novel drugs can eradicate or modify the natural history of disease. I believe that widespread use of JAK inhibitors in PV or ET should be limited to selected cases as safety of their long-term use remains uncertain. Abbreviations: ET, essential thrombocythemia; PMF, primary myelofibrosis; PV, polycythemia vera.
